News Report · Nephrology

FDA Approves Finerenone for CKD: 18% Risk Reduction in FIDELIO-DKD Trial

June 10, 2026

Clinical Perspective

Finerenone represents a significant advancement in the management of chronic kidney disease associated with type 2 diabetes, offering a new therapeutic option that addresses both renal and cardiovascular risks.

Dr. Praveen Singh · Nephrology

Finerenone (Kerendia) reduced the risk of composite kidney and cardiovascular events by 18% versus placebo in patients with chronic kidney disease associated with type 2 diabetes in the FIDELIO-DKD trial (HR 0.82; 95% CI 0.73-0.93) ^[1].

Clinical Context

Chronic kidney disease (CKD) is a progressive condition characterized by the gradual loss of kidney function, often leading to kidney failure and cardiovascular complications. It is commonly associated with type 2 diabetes, which is the leading cause of CKD in the United States. Current treatment options primarily focus on managing blood glucose levels and controlling blood pressure, but many patients still experience disease progression and associated risks. The FIDELIO-DKD trial evaluated the efficacy of finerenone, a non-steroidal mineralocorticoid receptor antagonist, in reducing the risk of kidney and heart complications in this high-risk population.

Key Findings

The FIDELIO-DKD trial showed finerenone reduced the risk of composite kidney and cardiovascular events by 18% versus placebo (HR 0.82; 95% CI 0.73-0.93) ^[1].
The trial enrolled 5,674 adults with chronic kidney disease associated with type 2 diabetes ^[1].
Event rates: 504 of 2,833 patients receiving finerenone experienced at least one event in the composite endpoint compared to 600 of 2,841 patients receiving placebo ^[1].
The primary endpoint was a composite of at least a 40% reduction in estimated glomerular filtration rate (eGFR), progression to kidney failure, or kidney death ^[1].
Secondary endpoint results showed 367 patients receiving finerenone had cardiovascular events compared to 420 in the placebo group ^[1].
Finerenone is administered at a starting dose of 10 mg or 20 mg orally once daily, depending on eGFR and serum potassium levels ^[1].
Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

Hyperkalemia reported with finerenone — monitor during treatment ^[1].
Hypotension reported — exact frequency not available in public source summary ^[1].
Hyponatremia reported ^[1].
Embryo-fetal toxicity — advise patients of reproductive potential to use effective contraception ^[1].
Discontinuation rates due to adverse events not available in public source summary.
Complete adverse event profile available in the full prescribing information for finerenone (Kerendia) ^[1].

What This Means for Clinical Practice

Finerenone is indicated for adults with chronic kidney disease associated with type 2 diabetes who meet trial criteria. The data supports an 18% reduction in the risk of kidney and cardiovascular events, making it a valuable treatment option in this population. What are the long-term effects of finerenone on kidney function and cardiovascular health?

Study Design

The FIDELIO-DKD trial was a randomized, multicenter, double-blind, placebo-controlled study involving 5,674 patients with chronic kidney disease associated with type 2 diabetes. The primary endpoint assessed was a composite of at least a 40% reduction in eGFR, progression to kidney failure, or kidney death, with a follow-up duration of approximately 2.5 years. The trial was funded by Bayer Healthcare, and key limitations include the need for further data on long-term outcomes and the generalizability of results across diverse populations.

FAQ

What is finerenone (Kerendia) approved for?

Finerenone is approved for reducing the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes.

How does finerenone work?

Finerenone is a non-steroidal mineralocorticoid receptor antagonist that helps to reduce inflammation and fibrosis in the kidneys, thereby slowing the progression of chronic kidney disease.

What is the recommended dose of finerenone?

The recommended starting dose of finerenone is 10 mg or 20 mg orally once daily, based on estimated glomerular filtration rate (eGFR) and serum potassium thresholds. Clinicians should consult current prescribing information for full dosing guidance.

What are the most common side effects of finerenone?

Common side effects of finerenone include hyperkalemia, hypotension, and hyponatremia.

How does finerenone compare to placebo?

In the FIDELIO-DKD trial, finerenone reduced the risk of composite kidney and cardiovascular events by 18% compared to placebo.

FDA Approves Finerenone for CKD: 18% Risk Reduction in FIDELIO-DKD Trial

FDA Approves Finerenone for CKD: 18% Risk Reduction in FIDELIO-DKD Trial

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Study Design

FAQ

References

Get weekly drug updates for Nephrology in your inbox.

Related Drug Updates

FDA Approves Sparsentan for Proteinuria Reduction: PDUFA June 2026 in FSGS Patients

Verified HCP Portal